| 2008 | A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R-2 MRI | 성주명 | Meeting Abstract |
| 2010 | A Multi-Center, Open Label Study Evaluating the Efficacy, of Iron Chelation Therapy with Deferasirox In Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R-2 mri | 성주명 | Meeting Abstract |
| 2022 | A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naive, high-risk essential thrombocythemia as a primary treatment | 문영철 | Article |
| 2015 | Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome | 문영철 | Article |
| 2021 | Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-18-FDG PET/CT | 문영철 | Article |
| 2012 | Different Characteristics Identified by Single Nucleotide Polymorphism Array Analsysis in Leukemia Suggest the Need for Different Application Strategics Depending On Disease Category | 허정원 | Meeting Abstract |
| 2009 | Efficacy of ICT with Deferasirox in Transfusional Iron Overloaded Patients with MDS or AA | 성주명 | Meeting Abstract |
| 2010 | Genome-Wide Single-Nucleotide Polymorphism-Array Based Karyotyping Detects Clonal Aberrations and Predicts the Risk of Imatinib Failure In Chronic Myeloid Leukemia | 허정원 | Meeting Abstract |
| 2010 | Genome-Wide Single-Nucleotide Polymorphism-Array Based Karyotyping Detects Clonal Aberrations Including Uniparental Disomy (UPD), Gain or Loss Which Were Unfavorable Prognostic Factor In Acute Myeloid Leukemia with Normal Karyotype | 허정원 | Meeting Abstract |
| 2011 | Genome-Wide Single-Nucleotide Polymorphism-Array Can Improve Prognostic Stratification of Core Binding Factor Acute Myeloid Leukemia, Especially in the Subgroup with Inv(16)/t(16;16) or without D816 C-KIT Mutation | 허정원 | Meeting Abstract |
| 2011 | Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study | 성주명 | Meeting Abstract |
| 2012 | Hepatitis B Virus Reactivation in Chronic Myeloid Leukemia Treated with Various Tyrosine Kinase Inhibitors: Multicenter, Retrospective Study | 문영철 | Meeting Abstract |
| 2020 | Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis | 문영철 | Article |
| 2011 | Nilotinib Combined with Multi-Agent Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Interim Results of Korean Adult ALL Working Party Phase 2 Study | 문영철 | Meeting Abstract |
| 2015 | Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia | 문영철 | Article |
| 2021 | Pediatric-inspired regimen with late intensifi- cation and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study | 김대영 | Article |
| 2012 | Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party | 성주명 | Meeting Abstract |
| 2007 | Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (VELCADE (R), thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with VELCADE for newly diagnosed multiple myeloma: Interim results of phase II trial | 성주명 | Meeting Abstract |
